48
Participants
Start Date
August 3, 2023
Primary Completion Date
February 28, 2026
Study Completion Date
August 31, 2026
RC118
Dose A or dose B, Q2W
Toripalimab
Fixed dose, Q3W
RC148
Fixed dose, Q3W Other Names: RC148 injection
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
The First Affiliated Hospital of Xiamen University, Xiamen
RECRUITING
Gansu Wuwei Tumour Hospital, Wuwei
RECRUITING
Meizhou People's Hospital, Meizhou
RECRUITING
Harbin Medical University Cancer Hospital, Harbin
RECRUITING
Nanyang Central Hospital, Nanyang
RECRUITING
Xinyang Central Hospital, Xinyang
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
RECRUITING
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
RECRUITING
Xuzhou Central Hospital, Xuzhou
RECRUITING
The First Affiliated Hospital of Bengbu Medical University, Bengbu
RECRUITING
Cancer Hospital of Shandong First Medical University, Jinan
RECRUITING
Changzhi People's Hospital, Changzhi
RECRUITING
West China Hospital Sichuan University, Chengdu
RECRUITING
The Second People's Hospital of Neijiang, Neijiang
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
RECRUITING
Zhongshan Hospital Fudan University, Shanghai
RemeGen Co., Ltd.
INDUSTRY